Investor Relations

Latest Presentation

Corporate Presentation

Latest Financial Results

FY 2023

Fiscal Year Ended Aug 31, 2023

Latest Annual Filing

For Fiscal Year Ending Aug 31, 2023

Company Overview

Lexaria Bioscience Corp.'s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 37 patents granted and many patents pending worldwide.

Stock Snapshot

IR Contacts


Canadian Operations

#100-740 McCurdy Road
Kelowna, BC V1X 2P7

US Operations

2226 W. Northern Avenue
Phoenix, AZ 85021

Investor Relations

IR contact
T: 250-765-6424 ext. 202

Transfer Agent

Computershare Investor Services Inc.
T: 800-564-6253

Market Data copyright © 2023 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

Back to the top